paclitaxel albumin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
paclitaxel albumin: clinical details
Prescribing considerations
- Restrict preparation and administration to personnel trained in cytotoxic therapy under specialist oncology supervision.
- Assess performance status, comorbidity, infection risk, neuropathy and hepatic function; carefully assess older patients with pancreatic cancer before combination treatment.
- Review pregnancy potential, contraception and fertility preservation before treatment.
- Distinguish clearly from conventional paclitaxel at prescribing, dispensing, preparation and administration stages.
Contraindications and cautions
- Hypersensitivity to paclitaxel or an excipient
- Breastfeeding
- Baseline neutrophil count below the product-specified threshold
Monitoring
- Full blood count, particularly neutrophils and platelets
- Peripheral sensory and motor neuropathy
- Liver function and evidence of increased myelosuppression in hepatic impairment
- Fever, sepsis and other infection indicators
- New respiratory symptoms suggesting pneumonitis
- Cardiac symptoms in patients with relevant history or prior cardiotoxic treatment
- Visual change requiring prompt ophthalmological assessment
- Infusion site for infiltration or extravasation
Clinical pharmacology
Paclitaxel stabilises tubulin microtubules and prevents their normal depolymerisation, disrupting interphase and mitosis. It is mainly metabolised through CYP2C8 and CYP3A4 and cleared predominantly by hepatic metabolism and biliary excretion.
Formulation and product differences
- Albumin-bound paclitaxel has substantially different pharmacological and administration properties from conventional solvent-based paclitaxel and is not interchangeable with it.
- The powder contains paclitaxel formulated as albumin-bound nanoparticles and human albumin with sodium caprylate and N-acetyl-L-tryptophan.
- The reconstituted product is a white-to-yellow milky dispersion and requires the product-specified filter during administration.
- The formulation is essentially sodium-free.
paclitaxel albumin preparations and strengths
Dispersion for infusion
Route: Intravenous
Strengths: 5 mg/mL
paclitaxel albumin interactions
The cancer team should review all medicines, including non-prescription and herbal products. Important examples include:
CYP2C8 or CYP3A4 inhibitors, including azole antifungals, erythromycin, some HIV medicines, gemfibrozil and clopidogrel
These may increase paclitaxel exposure and toxicity, so additional caution and review are needed.
CYP2C8 or CYP3A4 inducers, including rifampicin, carbamazepine, phenytoin, efavirenz and nevirapine
These may lower paclitaxel exposure and compromise effectiveness; concurrent use is not recommended by the product information.
Erlotinib
It should not be co-administered with paclitaxel albumin plus gemcitabine.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.